Panda Arabind
Senior Consultant Urologist, KIMS, Secunderabad, India.
Transl Androl Urol. 2018 Aug;7(4):653-658. doi: 10.21037/tau.2018.04.07.
Stem cell therapy can potentially disrupt conventional medicine as we practice it today. Stem cells can self-renew and differentiate and by this, repair and in certain conditions regenerate damaged tissue. In the past two decades, there has been significant research into its value in several chronic urological conditions for which conventional therapy is unsatisfactory. Stem cell therapy has been tried on animal models of bladder dysfunction, stress urinary incontinence (SUI), erectile dysfunction and urethral injury and certain preclinical studies have had very encouraging results. Yet despite this explosion of knowledge about the nature and value of stem cells, translation of research into the clinical domain has been slow. In addition, lack of regulation of stem cell therapy has resulted in indiscriminate, unscientific administration of stem cell therapy to patients. This review looks into the advances in the use of stem cells in urological practice, the recent regulatory guidelines that have been introduced and what the future holds for this exciting branch.
干细胞疗法可能会颠覆我们如今所践行的传统医学。干细胞能够自我更新和分化,借此修复并在某些情况下再生受损组织。在过去二十年里,针对其在几种传统疗法效果欠佳的慢性泌尿系统疾病中的价值,已经开展了大量研究。干细胞疗法已在膀胱功能障碍、压力性尿失禁(SUI)、勃起功能障碍和尿道损伤的动物模型上进行了试验,某些临床前研究取得了非常令人鼓舞的结果。然而,尽管关于干细胞的性质和价值的知识激增,但将研究转化到临床领域的进程却很缓慢。此外,干细胞疗法缺乏监管导致对患者进行了随意、不科学的干细胞治疗。这篇综述探讨了干细胞在泌尿外科实践中的应用进展、最近出台的监管指南以及这个令人兴奋的领域的未来发展。